Efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma.
Loading...
Date
2014-11
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: This prospective, open, randomized, parallel-group, comparative
study is to evaluate the efficacy and side-effect profile of travoprost (TRAV) 0.004%
compared with tafluprost (TAF) 0.0015% in patients with primary open-angle
glaucoma (POAG) over 12 weeks. A total of 80 patients of POAG selected and
were randomized to either TRAV or TAF monotherapy administered once daily in
the evening for 12 weeks.
Methods: The study was conducted on 80 cases of POAG, in which patients were
randomized to either TRAV or TAF monotherapy administered as 1 drop daily in
the evening for 12 weeks. Intraocular pressure (IOP) was measured (8 am, 12 noon
and 4 pm) at each visit, slit-lamp bio-microscopy was done and side effects noted.
Results: The mean IOP reduction in TRAV group decreased from 27.58±2.30 to
19.03±2.326 thus resulting in fall of 8.55 (31.0%) and in TAF group it decreased from
27.38±2.676 to 20.58±2.827 resulting in fall of 6.8 mm Hg (24.8%) was significant
(p<0.05). In both treatment groups, the most frequently reported adverse event at
12 weeks was red eye, noted in, 9 (22.5%) and 7 (17.5%) cases of TRAV and TAF
groups respectively, though the difference was not statistically significant.
Conclusion: TRAV 0.004% monotherapy produced lower diurnal IOP than TAF
0.0015% in patients with POAG and exhibited a similar safety profile.
Description
Keywords
Primary open-angle glaucoma, Intraocular pressure, Tafluprost, Travoprost
Citation
Bachkheti Nisha, Chalia Dharamvir, Sehgal Vijay Kumar, Walia Sachin. Efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma. International Journal of Basic & Clinical Pharmacology. 2014 Nov-Dec; 3(6): 958-963.